The 340B Contract Pharmacy Landscape Has Fundamentally Changed
The 340B Drug Pricing Program was designed to help safety-net providers stretch scarce resources. For decades, covered entities used contract pharmacy arrangements to extend 340B pricing to patients filling prescriptions at retail pharmacies. That model is now under sustained attack.
As of early 2026, 39 drug manufacturers have imposed restrictions on 340B pricing for drugs dispensed through contract pharmacies. Some require claims-level data submission. Others limit 340B pricing to a single contract pharmacy per covered entity. A few have attempted to eliminate contract pharmacy access entirely.
For FQHCs, DSH hospitals, and other covered entities that rely on contract pharmacy revenue, navigating this landscape requires both legal awareness and operational discipline.
Understanding the Manufacturer Restrictions
Manufacturer restrictions generally fall into three categories. The first category requires covered entities to submit claims-level data through a designated third-party platform, typically 340B ESP, to access 340B pricing at contract pharmacies. Entities that submit the data retain access; those that do not lose 340B pricing on that manufacturer’s drugs at contract pharmacy locations.
The second category limits covered entities to a single contract pharmacy arrangement per covered entity site. This forces organizations with multiple contract pharmacy partners to choose which relationship to maintain.
The third category, most recently expanded by Eli Lilly, requires claims-level data submission not only for contract pharmacies but also for the covered entity’s own in-house pharmacy. This signals a broader trend toward manufacturer oversight of all 340B utilization, not just contract pharmacy dispensing.
Each manufacturer has different requirements, different deadlines, and different platforms. Managing compliance across 39 different restriction policies is a full-time operational challenge.
The Legal Landscape After AHA v. Kennedy
The legal fight over manufacturer restrictions has produced mixed results. In February 2026, the U.S. District Court for the District of Maine vacated the HRSA 340B Rebate Model Pilot Program in AHA v. Kennedy, ruling that HHS exceeded its statutory authority. This was a significant victory for covered entities, as the rebate model would have shifted from upfront discounts to post-sale rebates, creating cash flow challenges for safety-net providers.
However, the court ruling did not directly address manufacturer restrictions on contract pharmacies. Those restrictions continue to operate under separate legal theories, and litigation challenging them has produced inconsistent results across federal circuits.
At least eight states have enacted legislation prohibiting manufacturer restrictions on 340B contract pharmacy arrangements. But state laws only apply within their borders, and manufacturers have challenged several of these statutes in court.
The bottom line: covered entities cannot rely on litigation alone to restore full contract pharmacy access. Operational compliance strategies are essential.
Building a Compliant Response Strategy
Start with a complete inventory of your contract pharmacy arrangements and the manufacturers whose drugs flow through each one. Map each manufacturer’s specific restriction policy to your current operations. Identify gaps where you are at risk of losing 340B pricing.
For manufacturers requiring claims-level data, evaluate whether submission is operationally feasible and financially justified. The cost of data submission infrastructure must be weighed against the 340B savings at stake. For most large covered entities, the math favors compliance.
For manufacturers limiting contract pharmacy arrangements, analyze your dispensing volume by location. Prioritize the contract pharmacy relationship that captures the most 340B-eligible volume.
Document everything. HRSA audits continue, and the GAO has flagged weaknesses in HRSA’s oversight processes. Your internal compliance documentation should demonstrate that you are preventing diversion, avoiding duplicate discounts, and accurately tracking 340B-eligible patients across all dispensing channels.
Consider working with an MSO partner that has 340B compliance expertise. The operational complexity of managing 39 different manufacturer policies while maintaining HRSA compliance exceeds the capacity of most in-house pharmacy teams.
The HRSA RFI: Your Voice Matters
HRSA is currently accepting responses to a Request for Information on the potential use of rebates to effectuate 340B ceiling prices. Responses are due by April 20, 2026. This is your opportunity to shape the future of the program.
Covered entities should submit comments explaining how rebate models would affect cash flow, patient access, and program sustainability. The more specific and data-driven your response, the more weight it carries.
The 340B program remains essential to the safety-net mission. Protecting it requires both legal advocacy and operational excellence.
Disclaimer
This article is for educational purposes only and does not constitute legal advice. Covered entities should consult qualified legal counsel regarding 340B compliance and manufacturer restriction policies.
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Nexwell Health Partners provides management services, telehealth solutions, and compliance support for safety-net hospitals, FQHCs, and specialty practices. Contact us to schedule a consultation.
Sources